Subcutaneous

Edit

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

PR Newswire 20 Jan 2026

"We are excited to expand our Hybrozyme™ technology by collaborating with Tesaro in the oncology field, and look forward to developing and bringing this potential subcutaneous medicine to market," said Tae-Yon Chun, Ph.D., CEO of Alteogen.

Edit

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

PR Newswire 20 Jan 2026

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans.

Edit

Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and

Hastings Tribune 14 Jan 2026

Exton, PA, Jan ... oncologists. The research .

Edit

Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across ...

Nasdaq Globe Newswire 14 Jan 2026

US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible ...

Edit

Peptide Therapeutics Market Report 2025-2035: Industry to Experience Robust Growth with a CAGR of 6.8% Through 2035 - Subcutaneous Route to Command Over 65% Share - ResearchAndMarkets.com

Pharmiweb 14 Jan 2026

DUBLIN--(BUSINESS WIRE)--The "Peptide Therapeutics Market ... Market Insights ... Market Segmentation and Regional Insights ... Subcutaneous administration prevails due to enhanced efficacy, comprising 65% of the market ... Key Industry Players ... Report Coverage ... No ... .

Edit

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s ...

Nasdaq Globe Newswire 06 Jan 2026

If approved, lecanemab may become the first and only anti-amyloid treatment ...

Edit

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China (Biogen Inc)

Public Technologies 06 Jan 2026

This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab (marketed as 乐意保 in China); ...

Edit

BLA for subcutaneous formulation of Leqembi® accepted in China

PR Newswire 06 Jan 2026

BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector ... BLA for subcutaneous formulation of Leqembi accepted in China.

Edit

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's ...

JCN Newswire 06 Jan 2026

Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector.

Edit

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma (Johnson & Johnson)

Public Technologies 06 Jan 2026

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma.

Edit

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Pharmiweb 06 Jan 2026

Teclistamab is an off-the-shelf (or ready-to-use) bispecific antibody.[7],[8] Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body’s immune system to fight cancer.

Edit

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

The Eagle-Tribune 22 Dec 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 22, 2025-- ... .

Edit

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

Nasdaq Globe Newswire 22 Dec 2025

RHHBY) announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...

Edit

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus

Pharmiweb 16 Dec 2025

Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion ... Clinicaltrials.gov Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (Tulip-SC).

Edit

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus (Form 6-K) (AstraZeneca plc)

Public Technologies 16 Dec 2025

Subcutaneous Saphnelo approved in EU ... Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus ... Saphnelo subcutaneous administration.

Podcasts:

Latest News for: subcutaneous

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and

Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across ...

Peptide Therapeutics Market Report 2025-2035: Industry to Experience Robust Growth with a CAGR of 6.8% Through 2035 - Subcutaneous Route to Command Over 65% Share - ResearchAndMarkets.com

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s ...

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China (Biogen Inc)

BLA for subcutaneous formulation of Leqembi® accepted in China

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's ...

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma (Johnson & Johnson)

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus (Form 6-K) (AstraZeneca plc)

Article Search

EXPLORE WN.com